De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder

Molecular Psychiatry

Volumn 18, Issue 12, 2013, Pages 1315-1323

  Hamilton, P J ^a   Campbell, N G ^a   Sharma, S ^a   Erreger, K ^a   Herborg Hansen, F ^b   Saunders, C ^a   Belovich, A N ^a   Daly, M J ^e   Gibbs, R A ^e   Boerwinkle, E ^e   Buxbaum, J D ^e   Cook, E H ^d,e   Devlin, B ^e   Lim, E T ^e   Neale, B M ^e   Roeder, K ^e   Sabo, A ^e   Schellenberg, G D ^e   Stevens, C ^e   Sutcliffe, J S ^a,e   Sahai, M A ^c   Gether, U ^b   Mchaourab, H S ^a   Matthies, H J G ^a   Galli, A ^a   more..

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NONE

Author keywords

anomalous dopamine efflux; autism spectrum disorder; de novo mutation; dopamine; Drosophila melanogaster; transporter

Indexed keywords

ALANINE; DOPAMINE; DOPAMINE TRANSPORTER; METHIONINE;

ANIMAL CELL; ARTICLE; AUTISM; CASE REPORT; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; GENE EXPRESSION; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; MALE; MISSENSE MUTATION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; DROSOPHILA MELANOGASTER; HOMEOSTASIS; HUMANS; MALE; MOTOR ACTIVITY; MUTATION, MISSENSE; RISK FACTORS;

EID: 84888300021     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.102     Document Type: Article

References (80)

1. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev 2012; 22: 229-237.
2. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012; 485: 237-241.
3. Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011; 70: 863-885.
4. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T et al. Strong association of de novo copy number mutations with autism. Science 2007; 316: 445-449.
5. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466: 368-372.
6. Levy D, Ronemus M, Yamrom B, Lee YH, Leotta A, Kendall J et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 2011; 70: 886-897.
7. Cook Jr. EH, Scherer SW. Copy-number variations associated with neuropsychiatric conditions. Nature 2008; 455: 919-923.
8. Neale BM, Kou Y, Liu L, Maayan A, Samocha KE, Sabo A et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012; 485: 242-245.
9. ORoak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012; 485: 246-250.
10. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012; 74: 285-299.
11. Bjorklund A, Dunnett SB. Fifty years of dopamine research. Trends Neurosci 2007; 30: 185-187.
12. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 1993; 14: 43-49.
13. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Ann Rev Neurosci 1987; 10: 19-40.
14. Palmiter RD. Dopamine signaling in the dorsal striatum is essential for motivated behaviors: Lessons from dopamine-deficient mice. Ann N Y Acad Sci 2008; 1129: 35-46.
15. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinsons disease and schizophrenia. FASEB J 1990; 4: 2737-2744.
16. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 932-940.
17. Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord 2009; 11: 787-806.
18. Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M et al. Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. ArchGen Psychiatry 2010; 67: 59-68.
19. Anderson BM, Schnetz-Boutaud N, Bartlett J, Wright HH, Abramson RK, Cuccaro ML et al. Examination of association to autism of common genetic variationin genes related to dopamine. Autism Res 2008; 1: 364-369.
20. Gadow KD, Roohi J, DeVincent CJ, Hatchwell E. Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder. J Child Psychol Psychiatry 2008; 49: 1331-1338.
21. Hettinger JA, Liu X, Schwartz CE, Michaelis RC, Holden JJA. DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 628-636.
22. Staal WG, de Krom M, de Jonge MV. Brief report: The dopamine-3-receptor gene (DRD3) is associated with specific repetitive behavior in autism spectrum disorder (ASD). J Autism Dev Disord 2012; 42: 885-888.
23. de Krom M, Staal WG, Ophoff RA, Hendriks J, Buitelaar J, Franke B et al. A common variant in DRD3 receptor is associated with autism spectrum disorder. Biol Psychiatry 2009; 65: 625-630.
24. Gadow KD, Devincent CJ, Olvet DM, Pisarevskaya V, Hatchwell E. Association of DRD4 polymorphism with severity of oppositional defiant disorder, separation anxiety disorder and repetitive behaviors in children with autism spectrum disorder. Eur J Neuroscience 2010; 32: 1058-1065.
25. Makkonen I, Kokki H, Kuikka J, Turpeinen U, Riikonen R. Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. Neuropediatrics 2011; 42: 207-209.
26. Nieminen-Von Wendt TS, Metsahonkala L, Kulomaki TA, Aalto S, Autti TH, Vanhala R et al. Increased presynaptic dopamine function in Asperger syndrome. Neuroreport 2004; 15: 757-760.
27. Tassone F, Qi L, Zhang W, Hansen RL, Pessah IN, Hertz-Picciotto I. MAOA, DBH, and SLC6A4 variants in CHARGE: A case-control study of autism spectrum disorders. Autism Res 2011; 4: 250-261.
28. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ et al. SLC6 neurotransmitter transporters: Structure, function, and regulation. Pharmacol Rev 2011; 63: 585-640.
29. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 2005; 102: 3495-3500.
30. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME et al. N-Terminal phosphorylation of the dopamine transporter is required for amphetamineinduced efflux. PLoS Biol 2004; 2: E78.
31. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-612.
32. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 1998; 18: 1979-1986.
33. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol 2005; 75: 406-433.
34. Kurian MA, Zhen J, Cheng SY, Li Y, Mordekar SR, Jardine P et al. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 2009; 119: 1595-1603.
35. Kurian MA, Li Y, Zhen J, Meyer E, Hai N, Christen HJ et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: An observational cohort and experimental study. Lancet Neurol 2011; 10: 54-62.
36. Grunhage F, Schulze TG, Muller DJ, Lanczik M, Franzek E, Albus M et al. Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry 2000; 5: 275-282.
37. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 2005; 49: 724-736.
38. Ronald A, Simonoff E, Kuntsi J, Asherson P, Plomin R. Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry 2008; 49: 535-542.
39. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J et al. Comorbid psychiatric disorders in children with autism: Interview development and rates of disorders. J Autism Dev Disord 2006; 36: 849-861.
40. Roman T, Rohde LA, Hutz MH. Polymorphisms of the dopamine transporter gene: Influence on response to methylphenidate in attention deficit- hyperactivity disorder. Am J Pharmacogenomics 2004; 4: 83-92.
41. de Bruin EI, de Nijs PF, Verheij F, Hartman CA, Ferdinand RF. Multiple complex developmental disorder delineated from PDD-NOS. J Autism Dev Disord 2007; 37: 1181-1191.
42. Nemoda Z, Szekely A, Sasvari-Szekely M. Psychopathological aspects of dopaminergic gene polymorphisms in adolescence and young adulthood. Neurosci Biobehav Rev 2011; 35: 1665-1686.
43. Dichter GS, Damiano CA, Allen JA. Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: Animal models and clinical findings. J Neurodeve Disord 2012; 4: 19.
44. Goldstein S, Schwebach AJ. The comorbidity of Pervasive Developmental Disorder and Attention Deficit Hyperactivity Disorder: Results of a retrospective chart review. J Autism Dev Disord 2004; 34: 329-339.
45. Yoshida Y, Uchiyama T. The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry 2004; 13: 307-314.
46. Gadow KD, DeVincent CJ, Pomeroy J. ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord 2006; 36: 271-283.
47. Sturm H, Fernell E, Gillberg C. Autism spectrum disorders in children with normal intellectual levels: Associated impairments and subgroups. Dev Med Child Neurol 2004; 46: 444-447.
48. Di Martino A, Zuo XN, Kelly C, Grzadzinski R, Mennes M, Schvarcz A et al. Shared and distinct intrinsic functional network centrality in autism and attention-deficit/hyperactivity disorder. Biol Psychiatry 2013; S0006-3223: 00176-5.
49. Wolfson W. Boston Autism Consortium searches for genetic clues to autisms puzzle. ChemBiol 2007; 14: 117-118.
50. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24: 659-685.
51. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, Szatmari P et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2006; 45: 1094-1103.
52. Lord C, Risi S, Lambrecht L, Cook Jr. EH, Leventhal BL, DiLavore PC et al. The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000; 30: 205-223.
53. Bowton E, Saunders C, Erreger K, Sakrikar D, Matthies HJ, Sen N et al. Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J Neurosci 2010; 30: 6048-6057.
54. Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH et al. Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 2008; 28: 7040-7046.
55. Rickhag M, Hansen FH, Sorensen G, Strandfelt KN, Andresen B, Gotfryd K et al. A C-Terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter. Nat Commun 2013; 4: 1580.
56. Rasmussen TN, Plenge P, Bay T, Egebjerg J, Gether U. A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology 2009; 57: 287-294.
57. Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V et al. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol 2010; 8: E1000393.
58. Krishnamurthy H, Gouaux E. X-ray structures of LeuT in substrate-free outwardopen and apo inward-open states. Nature 2012; 481: 469-474.
59. Shan J, Javitch JA, Shi L, Weinstein H. The substrate-driven transition to an inwardfacing conformation in the functional mechanism of the dopamine transporter. PloS One 2011; 6: E16350.
60. Guptaroy B, Zhang M, Bowton E, Binda F, Shi L, Weinstein H et al. A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol Pharmacol 2009; 75: 514-524.
61. Claxton DP, Quick M, Shi L, de Carvalho FD, Weinstein H, Javitch JA et al. Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. Nat Struct Mol Biol 2010; 17: 822-829.
62. Jeschke G, Polyhach Y. Distance measurements on spin-labelled biomacromolecules by pulsed electron paramagnetic resonance. Phys Chem Chem Phys 2007; 9: 1895-1910.
63. Zou P, McHaourab HS. Increased sensitivity and extended range of distance measurements in spin-labeled membrane proteins: Q-band double electronelectron resonance and nanoscale bilayers. Biophys J 2010; 98: L18-L20.
64. Jeschke G, Koch A, Jonas U, Godt A. Direct conversion of EPR dipolar time evolution data to distance distributions. J Magn Reson 2002; 155: 72-82.
65. Kume K, Kume S, Park SK, Hirsh J, Jackson FR. Dopamine is a regulator of arousal in the fruit fly. J Neurosci 2005; 25: 7377-7384.
66. Friggi-Grelin F, Coulom H, Meller M, Gomez D, Hirsh J, Birman S. Targeted gene expression in Drosophila dopaminergic cells using regulatory sequences from tyrosine hydroxylase. J Neurobiol 2003; 54: 618-627.
67. Wang JW, Beck ES, McCabe BD. A modular toolset for recombination transgenesis and neurogenetic analysis of Drosophila. PloS One 2012; 7: E42102.
68. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE et al. An integrated map of genetic variation from 1092 human genomes. Nature 2012; 491: 56-65.
69. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-311.
70. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 2005; 437: 215-223.
71. Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A. Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem 2003; 278: 12070-12077.
72. McHaourab HS, Steed PR, Kazmier K. Toward the fourth dimension of membrane protein structure: Insight into dynamics from spin-labeling EPR spectroscopy. Structure 2011; 19: 1549-1561.
73. McHaourab HS, Lin YL, Spiller BW. Crystal structure of an activated variant of small heat shock protein Hsp16.5. Biochemistry 2012; 51: 5105-5112.
74. Zhao Y, Terry DS, Shi L, Quick M, Weinstein H, Blanchard SC et al. Substratemodulated gating dynamics in a Na+-coupled neurotransmitter transporter homologue. Nature 2011; 474: 109-113.
75. Wicker-Thomas C, Hamann M. Interaction of dopamine, female pheromones, locomotion and sex behavior in Drosophila melanogaster. J Insect Physiol. 2008; 54: 1423-1431.
76. Pendleton RG, Rasheed A, Sardina T, Tully T, Hillman R. Effects of tyrosine hydroxylase mutants on locomotor activity in Drosophila: A study in functional genomics. Behav Genet 2002; 32: 89-94.
77. Pizzo AB, Karam CS, Zhang Y, Yano H, Freyberg RJ, Karam DS et al. The membrane raft protein Flotillin-1 is essential in dopamine neurons for amphetamine-induced behavior in Drosophila. Molecular Psychiatry 2012; 18: 824-833.
78. Matthies HJ, Broadie K. Techniques to dissect cellular and subcellular function in the Drosophila nervous system. Methods Cell Biol 2003; 71: 195-265.
79. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 2008; 11: 780-789.
80. Bisgaard H, Larsen MA, Mazier S, Beuming T, Newman AH, Weinstein H et al. The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology 2011; 60: 182-190.